Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

Caen University Hospital

Status: Not yet enrolling

Conditions: Cancer

Treatments: Drug: Lenalidomide

Study type: Observational

Funder types: Other

Identifiers

NCT06251648

LenALL#01-02-2024

Details and patient eligibility

About

Although lenalidomide (LEN) have proved effective in treating many cancers, few patients receiving LEN may experience rare but life-threatening adverse events such as Acute Lymphoblastic Leukaemia (ALL). Today, data about ALL are scarce.

The objective was to investigate reports of ALL adverse events related to LEN in patients with cancer using the World Health Organization (WHO) pharmacovigilance database.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Case reported in the World Health Organization (WHO, also called VigiBase) at the time of the extraction
• Patients treated with at least LEN (L04AX04)

Exclusion criteria

-Chronology not compatible between LEN and ALL